Research programme: endothelial cell therapy (PVS 30200) - Shire

Drug Profile

Research programme: endothelial cell therapy (PVS 30200) - Shire

Alternative Names: Cancer cell therapy (PVS-30200); Cell-based oncology programme (PVS-30200) - Shire; Matrix-embedded endothelial cell-based therapy (PVS-30200) - Shire; PVS-30200

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pervasis Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours; Wounds

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in USA (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Wounds in USA
  • 19 Apr 2012 Shire acquires all the assets of Pervasis Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top